Tested leukemia treatment for mixed-type acute leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests a leukemia-based treatment for people with acute leukemia that doesn’t clearly belong to one type. It aims to improve outcomes for patients who meet specific health and heart/lab requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 14 years and have acute leukemia of unclear (“mixed”) type
- Your daily activity level is ECOG 2 (you can do self-care but may be up and about less than normal)
- Your heart tests are safe, including an ejection fraction of at least 45% and an ECG with no prolonged QT (after possible electrolyte correction)
- Your organ function and labs are in a safe range (liver, kidney, pancreas enzymes) and potassium, magnesium, and phosphorus are at or above the normal minimum
- You can sign an informed consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether venetoclax combined with azacitidine can help people with ALAL (an “ambiguous” type of acute leukemia). It also checks whether the combination is safe for newly diagnosed patients with adequate heart, liver, and kidney health.
This trial tests a combination of three drugs (revumenib, azacitidine, and venetoclax) for children and young adults with a hard-to-treat type of leukemia that has a specific genetic change. The goal is to see if this new mix can help when standard treatments have not worked.
This Phase 1/2 study tests enzomenib (DSP-5336) in people with relapsed or hard-to-treat acute leukemia (and, in some places, certain other blood cancers). The goal is to see how the drug works and how safe it is, especially for leukemia cases with specific genetic changes (KMT2A/MLL or NPM1).
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
This trial tests a new drug (S243249) for people with acute leukemia that has come back or not responded to treatment. It focuses on those with specific gene changes (KMT2A, NUP98, or NPM1c) and aims to see if the drug is safe and effective.
This trial tests different chemotherapy induction, consolidation (follow-up treatment), and strategies to prevent complications after an allogeneic stem cell transplant. It aims to improve overall survival and reduce serious transplant side effects like graft-versus-host disease (GVHD).
Hear when a new Acute Leukemia of Ambiguous Lineage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.